Global Endometrial Cancer Market Size study, by Type Of Cancer (Endometrial Carcinoma, Uterine Sarcomas), Type Of Therapy, Diagnosis Method and Regional Forecasts 2022-2032

Description

Global Endometrial Cancer Market is valued approximately at USD 15.1 billion in 2023 and is anticipated to grow with a compelling compound annual growth rate (CAGR) of 5.69% over the forecast period 2024-2032. Endometrial cancer, primarily affecting the lining of the uterus, stands as the most common gynecologic malignancy in developed nations. Increasing awareness about early screening techniques, rising obesity rates (a prominent risk factor), and growing access to hormone replacement therapy have heightened the need for advanced diagnostic and therapeutic solutions. Innovations in precision oncology and molecular diagnostics are rapidly transforming how healthcare providers detect, stratify, and manage this condition, particularly in its early stages when intervention is most effective.

The surge in demand for targeted therapy and immunotherapy, especially among patients showing resistance to first-line hormonal treatment, is one of the core forces reshaping the treatment paradigm. Researchers and pharmaceutical companies alike are doubling down on the development of more effective inhibitors, monoclonal antibodies, and combination regimens. Concurrently, diagnostic tools such as endometrial biopsies and transvaginal ultrasounds have witnessed widespread adoption due to their non-invasive nature and clinical reliability. Moreover, the evolution of genetic biomarkers and companion diagnostics is enabling oncologists to tailor treatment strategies that improve patient outcomes while minimizing side effects.

Despite such advances, the global endometrial cancer market grapples with considerable challenges, including delayed diagnoses in developing nations, limited therapeutic options for late-stage or recurrent cases, and disparities in healthcare access. However, these gaps are increasingly being addressed through the expansion of telemedicine platforms, global oncology awareness programs, and international partnerships aimed at bolstering clinical trial reach. Simultaneously, supportive regulatory frameworks are accelerating the market approval of breakthrough drugs and companion diagnostics, further fueling commercial interest in the sector.

Regionally, North America maintains a commanding position within the endometrial cancer treatment landscape, bolstered by a robust clinical infrastructure, higher rates of disease screening, and deep penetration of innovative biologics. Europe follows closely, driven by growing investment in women's health, centralized treatment protocols, and a surge in regulatory approvals across key economies such as Germany, the UK, and France. The Asia Pacific region is poised for the fastest growth, underpinned by improving access to healthcare services, escalating cancer awareness initiatives, and the rising incidence of lifestyle-related risk factors in rapidly urbanizing countries like India, China, and South Korea. Latin America and the Middle East & Africa are witnessing gradual growth as governments increase investment in oncology care and diagnostic capacity.

Major market player included in this report are:

Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
AstraZeneca PLC
F. Hoffmann-La Roche AG
Merck & Co., Inc.
Eisai Co., Ltd.
Eli Lilly and Company
GlaxoSmithKline plc
Amgen Inc.
Genentech, Inc.
Sanofi S.A.
Bayer AG
AbbVie Inc.
Teva Pharmaceutical Industries Ltd.

The detailed segments and sub-segment of the market are explained below:

By Type Of Cancer

Endometrial Carcinoma
Uterine Sarcomas

By Type Of Therapy

Chemotherapy
Immunotherapy
Hormonal Therapy
Targeted Therapy
Radiation Therapy
Surgery

By Diagnosis Method

Endometrial Biopsy
Hysteroscopy
Dilation and Curettage (D&C)
Transvaginal Ultrasound
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Endometrial Cancer Market Executive Summary

1.1. Global Endometrial Cancer Market Size & Forecast (2022 - 2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type of Cancer
- 1.3.2. By Type of Therapy
- 1.3.3. By Diagnosis Method
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Endometrial Cancer Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Endometrial Cancer Market Dynamics

3.1. Market Drivers
- 3.1.1. Rising Awareness of Early Screening and Diagnostic Techniques
- 3.1.2. Increasing Obesity Rates as a Key Risk Factor
- 3.1.3. Innovations in Precision Oncology and Molecular Diagnostics
3.2. Market Challenges
- 3.2.1. Delayed Diagnoses in Developing Nations
- 3.2.2. Limited Therapeutic Options for Late-Stage or Recurrent Disease
- 3.2.3. Disparities in Healthcare Access and Infrastructure
3.3. Market Opportunities
- 3.3.1. Surge in Demand for Targeted Therapy and Immunotherapy Regimens
- 3.3.2. Evolution of Genetic Biomarkers and Companion Diagnostics
- 3.3.3. Expansion of Telemedicine Platforms and Global Clinical Trial Partnerships

Chapter 4. Global Endometrial Cancer Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Endometrial Cancer Market Size & Forecasts by Type of Cancer (2022 - 2032)

5.1. Segment Dashboard
5.2. Endometrial Carcinoma: Revenue Trend Analysis, 2022 & 2032
5.3. Uterine Sarcomas: Revenue Trend Analysis, 2022 & 2032

Chapter 6. Global Endometrial Cancer Market Size & Forecasts by Type of Therapy (2022 - 2032)

6.1. Segment Dashboard
6.2. Chemotherapy: Revenue Trend Analysis, 2022 & 2032
6.3. Immunotherapy: Revenue Trend Analysis, 2022 & 2032
6.4. Hormonal Therapy: Revenue Trend Analysis, 2022 & 2032
6.5. Targeted Therapy: Revenue Trend Analysis, 2022 & 2032
6.6. Radiation Therapy: Revenue Trend Analysis, 2022 & 2032
6.7. Surgery: Revenue Trend Analysis, 2022 & 2032

Chapter 7. Global Endometrial Cancer Market Size & Forecasts by Diagnosis Method (2022 - 2032)

7.1. Segment Dashboard
7.2. Endometrial Biopsy: Revenue Trend Analysis, 2022 & 2032
7.3. Hysteroscopy: Revenue Trend Analysis, 2022 & 2032
7.4. Dilation and Curettage (D&C): Revenue Trend Analysis, 2022 & 2032
7.5. Transvaginal Ultrasound: Revenue Trend Analysis, 2022 & 2032
7.6. Others: Revenue Trend Analysis, 2022 & 2032

Chapter 8. Global Endometrial Cancer Market Size & Forecasts by Region (2022 - 2032)

8.1. North America Endometrial Cancer Market
- 8.1.1. U.S. Endometrial Cancer Market
  - 8.1.1.1. By Type of Cancer, 2022 - 2032
  - 8.1.1.2. By Type of Therapy, 2022 - 2032
  - 8.1.1.3. By Diagnosis Method, 2022 - 2032
- 8.1.2. Canada Endometrial Cancer Market
8.2. Europe Endometrial Cancer Market
- 8.2.1. UK Endometrial Cancer Market
- 8.2.2. Germany Endometrial Cancer Market
- 8.2.3. France Endometrial Cancer Market
- 8.2.4. Spain Endometrial Cancer Market
- 8.2.5. Italy Endometrial Cancer Market
- 8.2.6. Rest of Europe Endometrial Cancer Market
8.3. Asia Pacific Endometrial Cancer Market
- 8.3.1. China Endometrial Cancer Market
- 8.3.2. India Endometrial Cancer Market
- 8.3.3. Japan Endometrial Cancer Market
- 8.3.4. Australia Endometrial Cancer Market
- 8.3.5. South Korea Endometrial Cancer Market
- 8.3.6. Rest of Asia Pacific Endometrial Cancer Market
8.4. Latin America Endometrial Cancer Market
- 8.4.1. Brazil Endometrial Cancer Market
- 8.4.2. Mexico Endometrial Cancer Market
- 8.4.3. Rest of Latin America Endometrial Cancer Market
8.5. Middle East & Africa Endometrial Cancer Market
- 8.5.1. Saudi Arabia Endometrial Cancer Market
- 8.5.2. South Africa Endometrial Cancer Market
- 8.5.3. Rest of Middle East & Africa Endometrial Cancer Market

Chapter 9. Competitive Intelligence

9.1. Key Company SWOT Analysis
- 9.1.1. Pfizer Inc.
- 9.1.2. Novartis AG
- 9.1.3. Bristol-Myers Squibb Company
9.2. Top Market Strategies
9.3. Company Profiles
- 9.3.1. Pfizer Inc.
  - 9.3.1.1. Key Information
  - 9.3.1.2. Overview
  - 9.3.1.3. Financial (Subject to Data Availability)
  - 9.3.1.4. Product Summary
  - 9.3.1.5. Market Strategies
- 9.3.2. Novartis AG
- 9.3.3. Bristol-Myers Squibb Company
- 9.3.4. AstraZeneca PLC
- 9.3.5. F. Hoffmann-La Roche AG
- 9.3.6. Merck & Co., Inc.
- 9.3.7. Eisai Co., Ltd.
- 9.3.8. Eli Lilly and Company
- 9.3.9. GlaxoSmithKline plc
- 9.3.10. Amgen Inc.
- 9.3.11. Genentech, Inc.
- 9.3.12. Sanofi S.A.
- 9.3.13. Bayer AG
- 9.3.14. AbbVie Inc.
- 9.3.15. Teva Pharmaceutical Industries Ltd.